India Equity Research | Engineering & Capital Goods November 14, 2018 Result Update

Skipper

Refer to important disclosures at the end of this report

Forex losses weigh in on earnings

- Skipper reported a profit in Q2, and results were in line with our expectations but fell short
 of Street estimates. While operational performance was broadly in line, the profitability was
 impacted by MTM losses of ~Rs116mn on forex derivatives.
- Engineering Product (EP) segment revenues grew 3% yoy, while revenues of the Polymer Product (PP) segment declined 16% yoy. Excluding the impact of MTM losses, EBITDAM of the EP segment was 11% (12.9% yoy), while it was a mere 1.6% (11.1% yoy) for the PP segment.
- Management has reduced the guidance for the EP segment: ~10% revenue growth vs. 15% earlier, with EBIDTAM of ~11% vs. 13% earlier. Skipper has also approved the demerger of the PP division into Skipper Pipes Ltd (appointed date is April 1, 2018).
- We are cutting our FY19/20 EPS estimates by 26%/34% to factor in lower revenues and margins in the EP and PP segments. We introduce FY21 estimates, factoring in revenue growth of 16.3% over FY20E and EBITDAM of 11.3%. Maintain Buy, with a target price of Rs135 (based on SoTP method).
- Sluggish performance: Skipper's reported revenues of Rs5.2bn (+1.6% yoy) were below our estimates due to delays in project execution in the EP segment. While revenues of the EP segment increased 3% yoy to Rs4.8bn, the PP segment's revenues declined 16% yoy to Rs359mn. EBITM in the EP segment was down 513bps to 7.9% on MTM losses stemming from forex derivatives, higher commodity prices in fixed-price contracts, and delays in execution. Excluding the MTM losses, EP segment EBITDAM stood at 11%. Management commentary indicates that the aggregate MTM losses of ~Rs200mn in 1HFY19 would likely get reversed over the next few quarters as a major portion of the export backlog gets executed in 2HFY19 and 1HFY20.
- Maintain Buy: The order backlog in the EP segment remains steady at ~Rs24bn (1.35x FY18 EP sales), ensuring good revenue visibility over the next 12-15 months. While order flows in the domestic T&D have been receding in the last few quarters, management commentary suggests that major domestic orders worth Rs850bn are under the bidding stage (Rs100bn for Transmission projects in Northeast India, Rs250bn for the Raigarh Pugalur HVDC Transmission project, and Rs500bn of Green Corridor projects). In the international segment, the company had bidded for tenders worth Rs18bn and is hopeful of a better strike rate in light of the recent sharp depreciation of the INR. We believe that the diversification into non-T&D businesses such as Railways, Telecom, and Solar structures will help Skipper mitigate the decline in the domestic T&D. While Telecom and Solar are inherently low-margin businesses, Skipper would likely have to sacrifice margins in the initial orders in the Railway segment as it is in the process of building up references and qualifications. Going forward, we expect EP segment EBITM to settle at ~11% vs. the 14-15% range which the company had been reporting in the last four years. We maintain Buy, with a revised target price of Rs135. We derived the TP using the SoTP method based on FY21E EPS.

Financial Snapshot (Standalone)

(Rs mn)	FY17	FY18	FY19E	FY20E	FY21E
Net Sales	16,646	20,737	23,025	26,509	30,839
EBITDA	2,722	3,025	2,420	2,866	3,470
EBITDA Margin (%)	16.4	14.6	10.5	10.8	11.3
APAT	1,242	1,178	618	833	1,263
EPS (Rs)	12.1	11.5	6.0	8.1	12.3
EPS (% chg)	30.6	(5.4)	(47.5)	34.8	51.5
ROE (%)	27.2	20.1	9.4	11.7	15.9
P/E (x)	7.8	8.3	15.8	11.7	7.7
EV/EBITDA (x)	4.5	4.3	6.0	4.9	3.9
P/BV (x)	1.8	1.5	1.4	1.3	1.2

Sinkay[©] Your success is our success

СМР	Target Price
Rs 95 as of (November 13, 2018)	Rs 135 (▼) 12 months
Rating	Upside
BUY (∎)	41.3 %

Change in Estimates

onange in L.	sunna	103							
EPS Chg FY1	9E/F	Y20E (%	6)	(26)/(34)					
Target Price of	hang	e (%)		(18.4)					
Target Period	(Mor	nths)		12					
Previous Rec	0			BUY					
Emkay vs Co	nsen	sus							
EPS Estimates									
		F١	(19E	FY20E					
Emkay			6.0	8.1					
Consensus			10.3	14.0					
Mean Conser	isus 1	P (12M)	Rs 188					
Stock Details	5								
Bloomberg Co	ode		SK	IPPER IN					
Face Value (F	Rs)			1					
Shares outsta	Inding) (mn)		103					
52 Week H/L				293 / 83					
M Cap (Rs br	/USC	bn)		10/0.13					
Daily Avg Vol	ume (nos.)		2,39,935					
Daily Avg Tur	nover	(US\$ n	าท)	0.4					
Shareholding	g Pati	ern Se	p '18						
Promoters				71.4%					
FIIs				6.6%					
DIIs				9.5%					
Public and Ot	hers			12.5%					
Price Perform	nanc	e							
(%)	1M	3M	6N	I 12M					
Absolute	2	(21)	(50)) (63)					
Rel. to Nifty	1	(16)	(49)) (64)					
Relative pric	e cha	rt							
300 Rs				% 20					
256				- 2					
212 -	~\/*	4		16					
168 -		NA NA	An.	34					
124 -				52					
80			4	-70					
Nov-17 Jan-18	Mar-18 oper Ltd (Ll		Jul-18 Rel to Nifty	Sep-18 Nov-18					
Source: Bloom		10) — 1	(or to rainly	(((10)					
This report is sole following persone of the recommen	s) are	responsik							
John Perinch									
john.perinche	-	mkayglo	bal.c	om					
+91-022-6612	1374								

Nilesh Soni

nilesh.soni@emkayglobal.com +91-022-66121262

Source: Company, Emkay Research

Exhibit 1: Actual vs. Estimates

(Rs mn)	Actual	Estim	nates	% var	iation	Comment	
(13 1111)	Actual	Emkay	Consensus	Emkay	Consensus	Comment	
Sales	5,240	5,570	5,114	(6)	2	Lower than expected execution in EP segment	
EBITDA	388	453	473	(14)	(18)	MTM lesses on forey derivatives imposts EDIDTA	
EBITDA, margin	7.4%	8.1%	9.2%	-73bps	-184bps	MTM losses on forex derivatives impacts EBIDTA	
PAT	25	19	97	31	(74)	MTM losses and interest cost drags profitability	

Source: Company, Emkay Research

Exhibit 2: Quarterly Financials - Standalone

Rs mn	Q2FY19	Q2FY18	Q1FY19	YoY (%)	QoQ (%)	YTD FY18	YTD FY19	YoY (%)
Revenues	5,240	5,156	4,787	1.6	9.5	9,144	10,027	9.6
Material cost	3,630	3,458	3,253	5.0	11.6	5,928	6,883	16.1
as % of sales	69.3	67.1	68.0	222 bps	133 bps	64.8	68.6	382 bps
Employee Cost	236	251	235	(6.0)	0.7	461	471	2.0
as % of sales	4.5	4.9	4.9	-37 bps	-39 bps	5.0	4.7	-35 bps
Other expenditure	985	765	850	28.9	16.0	1,557	1,835	17.9
as % of sales	18.8	14.8	17.8	398 bps	106 bps	17.0	18.3	128 bps
Total expenditure	4,852	4,473	4,337	8.5	11.9	7,945	9,189	15.6
EBITDA	388	683	450	(43.2)	(13.7)	1,199	838	(30.1)
Depreciation	97	121	115	(19.9)	(16.2)	228	212	(7.1)
EBIT	291	562	335	(48.2)	(12.9)	971	626	(35.5)
Other Income	3	3	3	3.4	4.0	11	7	(38.7)
Interest	257	200	274	28.1	(6.4)	369	531	43.8
PBT	38	365	64	(89.5)	(39.9)	613	102	(83.3)
Taxes	13	133	19	(89.9)	(28.9)	221	32	(85.4)
Reported PAT	25	232	45	(89.3)	(44.6)	392	70	(82.2)
Adjusted EPS	0.2	2.3	0.4	(89.3)	(44.6)	3.8	0.7	(82.2)
Margins (%)				bps	bps			bps
Gross Margins	30.7	32.9	32.0	(222)	(133)	35.2	31.4	(382)
EBIDTAM	7.4	13.2	9.4	(584)	(199)	13.1	8.4	(476)
EBITM	5.6	10.9	7.0	(534)	(143)	10.6	6.2	(438)
PBTM	0.7	7.1	1.3	(635)	(60)	6.7	1.0	(569)
PATM	0.4	4.4	0.9	(403)	(46)	4.2	0.6	(354)
Effective Tax rate	34.9	36.4	29.5	(150)	542	36.0	31.5	(452)

Source: Company, Emkay Research

Exhibit 3: Segmental performance - Standalone

Rs in mn	Q2FY19	Q2FY18	Q1FY19	YoY (%)	QoQ (%)	YTD FY18	YTD FY19	YoY (%)
Segment Revenue								
Engineering Products	4,776	4,634	4,041	3.1	18.2	8,285	8,817	6.4
PVC Products	359	428	561	(16.1)	(36.0)	861	920	6.8
Infrastructure Projects	105	95	185	10.4	(43.6)	338	290	(14.2)
Total	5,240	5,156	4,787	1.6	9.5	9,483	10,027	5.7
Less : inter segment revenue	-	-	-			-	-	
Total	5,240	5,156	4,787	1.6	9.5	9,483	10,027	5.7
Segment Results								
Engineering Products	380	606	402	(37.4)	(5.5)	1,046	782	(25.2)
PVC Products	(11)	28	(7)	(138.3)	45.1	59	(18)	(130.9)
Infrastructure Projects	0	11	24	(96.2)	(98.2)	41	24	(40.5)
Total	369	645	418	(42.8)	(11.7)	1,145	787	(31.2)
Less- Unall (Exp)	78	83	84	(6.4)	(7.1)	174	162	(7.3)
Add Other Income	3	3	3	3.4	4.0	11	7	(38.7)
Less- Interest Exp	257	200	274	28.1	(6.4)	369	531	43.8
Other Exceptional Item	-	-	-			-	-	
PBT	38	365	64	(89.5)	(39.9)	613	102	(83.3)
Segment Margins (%)				bps	bps			bps
Engineering Products	7.9	13.1	9.9	-513	-200	12.6	8.9	-376
PVC Products	(3.0)	6.6	(1.3)	-960	-168	6.9	(2.0)	-885
Infrastructure Projects	0.4	11.9	12.9	-1,147	-1,244	12.1	8.4	-370
Average	7.0	12.5	8.7	-547	-169	12.1	7.9	-422

Source: Company, Emkay Research

Exhibit 4: Adjusted segmental performance (excluding the impact of forex gains/loss)

Segment	Financial Summary	Q2FY19	Q2FY18	Change %	H1FY19	H1FY18	Change %
Engineering Products	Net Revenue	4,776	4,634	3.1%	8,817	7,995	10.3%
	EBITDA (without Forex)	527	600	-12.2%	1,005	940	6.8%
	EBITDAM	11.0%	12.9%		11.4%	11.8%	
PVC Products	Net Revenue	359	428	-16.1%	920	812	13.3%
	EBITDA (without Forex)	6	48	-87.6%	12	83	-85.1%
	EBITDAM	1.6%	11.1%		1.3%	10.3%	
Infrastructure Projects	Net Revenue	105	95	10.3%	290	338	-14.2%
	EBITDA (without Forex)	2	11	-79.5%	26	41	-36.8%
	EBITDAM	2.1%	11.5%		9.0%	12.2%	
Total	Net Revenue	5,240	5,156	1.6%	10,027	9,145	9.6%
	EBITDA (without Forex)	535	658	-18.8%	1,043	1,065	-2.0%
	EBITDAM	10.2%	12.8%		10.4%	11.6%	

Source: Company, Emkay Research

Exhibit 5: Revision in earnings estimates

Y/E, Mar (Rs. mn)		FY19E			FY20E		FY21E
T/E, Mar (RS. IIII)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduce
Revenues	24,858	23,025	-7%	29,914	26,509	-11%	30,839
EBITDA	2,724	2,420	-11%	3,507	2,866	-18%	3,470
EBITDAM (%)	11.0%	10.5%	-45 bps	11.7%	10.8%	-91 bps	11.3%
APAT	839	618	-26%	1,266	833	-34%	1,263
EPS (Rs)	8.2	6.0	-26%	12.3	8.1	-34%	12.3

Source: Company, Emkay Research

Exhibit 6: Revenues and profitability assumptions

Particulars	FY2016	FY2017	FY2018	FY2019E	FY2020E	FY2021E
Segment Revenues						
Engineering Products	13,260	15,034	18,072	19,709	22,703	26,090
Growth %	13%	13%	20%	9%	15%	15%
Infrastructure Projects	277	805	855	898	988	1,087
Growth %	-40%	191%	6%	5%	10%	10%
PVC Products	1,525	2,132	2,149	2,417	2,818	3,662
Growth %	70%	40%	1%	12%	17%	30%
Total	15,062	17,972	21,076	23,025	26,509	30,839
Segment EBITM						
Engineering Products	14.6%	15.5%	14.7%	11.0%	11.0%	11.0%
Infrastructure Projects	15.5%	14.2%	12.6%	7.5%	10.0%	10.0%
PVC Products	10.8%	7.8%	7.0%	1.0%	3.0%	7.5%
Segment EBIT						
Engineering Products	1,937	2,336	2,648	2,168	2,497	2,870
Infrastructure Projects	43	114	108	67	99	109
PVC Products	165	166	151	24	85	275
Total	2,145	2,616	2,907	2,260	2,681	3,253
Corporate Expenditure	194	209	340	350	350	350
Operating Income	1,951	2,406	2,566	1,910	2,331	2,903
EBITDAM	14.6%	16.4%	14.6%	10.5%	10.8%	11.3%
OPM	13.0%	14.5%	12.4%	8.3%	8.8%	9.4%
Other Income	52	32	22	10	14	12
Finance & interest cost	570	671	784	968	1,063	973
PBT (Before Exceptional)	1,433	1,767	1,804	951	1,282	1,943
Taxes	482	525	626	333	449	680
Tax Rate	34%	30%	35%	35%	35%	35%
РАТ	951	1,242	1,178	618	833	1,263

Source: Company, Emkay Research

Exhibit 7: Segment PAT (FY2021)

Rs mn	Engineering	Infrastructure	Polymer	Other Inc	Total
EBIT	2,870	109	275	12	3,265
Less: Corporate expenditure	264	26	60		350
Less: Interest	732	73	167		973
PBT	1,874	9	47	12	1,943
Less: Tax	656	3	17	4	680
PAT	1,218	6	31	8	1,263

Source: Company, Emkay Research


Exhibit 8: Valuation summary (FY2021)

Valuation Summary (FY21)	PAT	P/E (x)	Valuation	per share
Engineering	1,218	11.0	13,399	131
Infrastructure	6	7.0	43	0
Polymer	31	12.0	369	4
Total Value			13,810	
No of Shares			103	
Target Price			135	

Source: Company, Emkay Research


Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Quarterly Financials




Source: Company, Emkay Research

Exhibit 10: EBIDTA and EBIDTAM





Source: Company, Emkay Research



Source: Company, Emkay Research


Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore





Source: Company, Emkay Research

Exhibit 13: Engineering Product - EBIT and EBITM



Source: Company, Emkay Research






Exhibit 15: PVC Product - EBIT and EBITM




Source: Company, Emkay Research






Source: Company, Emkay Research

Exhibit 17: Infrastructure Projects - EBIT and EBITM




Source: Company, Emkay Research

Financials




Source: Company, Emkay Research





Source: Company, Emkay Research



Source: Company, Emkay Research

Enkay Research is also available on www.enkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY17	FY18	FY19E	FY20E	FY21E
Net Sales	16,646	20,737	23,025	26,509	30,839
Expenditure	13,924	17,712	20,604	23,643	27,369
EBITDA	2,722	3,025	2,420	2,866	3,470
Depreciation	316	459	511	535	567
EBIT	2,406	2,566	1,910	2,331	2,903
Other Income	32	22	10	14	12
Interest expenses	671	784	968	1,063	973
РВТ	1,767	1,804	951	1,282	1,943
Тах	525	626	333	449	680
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	1,242	1,178	618	833	1,263
Adjusted PAT	1,242	1,178	618	833	1,263

Balance Sheet

Y/E Mar (Rs mn)	FY17	FY18	FY19E	FY20E	FY21E
Equity share capital	102	103	103	103	103
Reserves & surplus	5,219	6,270	6,704	7,340	8,357
Net worth	5,321	6,373	6,806	7,443	8,459
Minority Interest	0	0	0	0	0
Loan Funds	2,618	3,305	5,000	4,500	4,000
Net deferred tax liability	626	539	539	539	539
Total Liabilities	8,565	10,217	12,345	12,481	12,998
Net block	4,968	5,209	5,048	4,862	4,746
Investment	0	0	0	0	0
Current Assets	8,796	12,211	12,515	14,513	16,611
Cash & bank balance	249	176	214	350	136
Other Current Assets	1,095	1,204	1,325	1,525	1,774
Current liabilities & Provision	5,344	7,219	5,218	6,894	8,359
Net current assets	3,453	4,992	7,297	7,619	8,252
Misc. exp	0	0	0	0	0
Total Assets	8,565	10,217	12,345	12,481	12,998

Cash Flow					
Y/E Mar (Rs mn)	FY17	FY18	FY19E	FY20E	FY21E
PBT (Ex-Other income) (NI+Dep)	1,736	1,782	941	1,268	1,931
Other Non-Cash items	0	0	0	0	0
Chg in working cap	1,169	(1,700)	(2,267)	(185)	(848)
Operating Cashflow	1,760	804	(179)	2,232	1,942
Capital expenditure	(1,176)	(571)	(334)	(350)	(450)
Free Cash Flow	584	233	(514)	1,882	1,492
Investments	0	0	0	0	0
Other Investing Cash Flow	353	131	0	0	0
Investing Cashflow	(791)	(419)	(325)	(336)	(438)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(2,064)	687	1,695	(500)	(500)
Dividend paid (incl tax)	(172)	(191)	(185)	(197)	(246)
Other Financing Cash Flow	1,807	(105)	0	0	0
Financing Cashflow	(1,100)	(392)	542	(1,760)	(1,719)
Net chg in cash	(132)	(7)	38	136	(215)
Opening cash position	498	249	176	214	350
Closing cash position	366	243	214	350	136

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Profitability (%)	FY17	FY18	FY19E	FY20E	FY21E
EBITDA Margin	16.4	14.6	10.5	10.8	11.3
EBIT Margin	14.5	12.4	8.3	8.8	9.4
Effective Tax Rate	29.7	34.7	35.0	35.0	35.0
Net Margin	7.5	5.7	2.7	3.1	4.1
ROCE	28.1	27.6	17.0	18.9	22.9
ROE	27.2	20.1	9.4	11.7	15.9
RolC	29.9	28.2	17.2	19.2	23.2
Per Share Data (Rs)	FY17	FY18	FY19E	FY20E	FY21E
EPS	12.1	11.5	6.0	8.1	12.3
CEPS	15.2	16.0	11.0	13.3	17.8
BVPS	52.0	62.1	66.4	72.6	82.5
DPS	1.9	2.0	1.8	1.9	2.4
	1.0	2.0	1.0	1.5	2.7
Valuations (x)	FY17	FY18	FY19E	FY20E	FY21E
PER	7.8	8.3	15.8	11.7	7.7
P/CEPS	6.3	6.0	8.7	7.1	5.3
P/BV	1.8	1.5	1.4	1.3	1.2
EV / Sales	0.7	0.6	0.6	0.5	0.4
EV / EBITDA	4.5	4.3	6.0	4.9	3.9
Dividend Yield (%)	2.0	2.1	1.9	2.0	2.5
Gearing Ratio (x)	FY17	FY18	FY19E	FY20E	FY21E
Net Debt/ Equity	0.4	0.5	0.7	0.6	0.5
Net Debt/EBIDTA	0.9	1.0	2.0	1.4	1.1
Working Cap Cycle (days)	70.2	84.8	112.3	100.1	96.1
One with (0/)	51/47	5)/40	51/405	EVOOE	
Growth (%)	FY17	FY18	FY19E	FY20E	FY21E
Revenue	10.5	24.6	11.0	15.1	16.3
EBITDA	24.2	11.1	(20.0)	18.4	21.1
EBIT	23.3	6.6	(25.6)	22.1	24.6
РАТ	30.6	(5.2)	(47.5)	34.8	51.5
	Q2FY18	Q3FY18	Q4FY18	Q1FY19	Q2FY19
Quarterly (Rs mn)	QZFIIO	401 110			
Quarterly (Rs mn) Revenue	5,156	5,664	5,929	4,787	5,240
				4,787 450	
Revenue	5,156	5,664	5,929		388
Revenue EBITDA	5,156 683	5,664 741	5,929 1,086	450	388 7. 4
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	5,156 683 13.2	5,664 741 13.1	5,929 1,086 18.3	450 9.4	388 7. 4 25
Revenue EBITDA EBITDA Margin (%) PAT	5,156 683 13.2 232	5,664 741 13.1 292	5,929 1,086 18.3 493	450 9.4 45	388 7. 4 25
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	5,156 683 13.2 232	5,664 741 13.1 292	5,929 1,086 18.3 493	450 9.4 45	388 7.4 25 0.2
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	5,156 683 13.2 232 2.3	5,664 741 13.1 292 2.9	5,929 1,086 18.3 493 4.8	450 9.4 45 0.4	388 7.4 25 0.2 Sep-18
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	5,156 683 13.2 232 2.3 Sep-17	5,664 741 13.1 292 2.9 Dec-17	5,929 1,086 18.3 493 4.8 Mar-18 70.2 6.2	450 9.4 45 0.4 Jun-18	388 7.4 25 0.2 Sep-18 71.4 6.6
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	5,156 683 13.2 232 2.3 Sep-17 70.4	5,664 741 13.1 292 2.9 Dec-17 70.4	5,929 1,086 18.3 493 4.8 Mar-18 70.2	450 9.4 45 0.4 Jun-18 70.2	5,240 388 7.4 25 0.2 Sep-18 71.4 6.6 9.5 12.5

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
14-Aug-18	119	165	12m	Buy	John Perinchery
21-May-18	179	279	12m	Buy	John Perinchery
20-Mar-18	229	297	12m	Buy	John Perinchery
06-Feb-18	238	297	12m	Buy	John Perinchery
30-Jan-18	221	327	12m	Buy	John Perinchery
14-Dec-17	259	327	12m	Buy	John Perinchery
27-Nov-17	277	327	12m	Buy	John Perinchery
18-Oct-17	214	282	12m	Buy	John Perinchery

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Rating Distribution

BUY	Expected total return (%) (Stock price appreciation and dividend yield) of over 25% within the next 12-18 months.
ACCUMULATE	Expected total return (%) (Stock price appreciation and dividend yield) of over 10% within the next 12-18 months.
HOLD	Expected total return (%) (Stock price appreciation and dividend yield) of upto 10% within the next 12-18 months.
REDUCE	Expected total return (%) (Stock price depreciation) of upto (-) 10% within the next 12-18 months.
SELL	The stock is believed to underperform the broad market indices or its related universe within the next 12-18 months.

Completed Date: 14 Nov 2018 11:16:21 (SGT) Dissemination Date: 14 Nov 2018 11:17:21 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

GENERAL DISCLOSURE/DISCLAIMER BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies. Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice. its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report. This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that: (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments well be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments well be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein. Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research reports, please refer to the

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of November 14, 2018
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of November 14, 2018.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 14, 2018
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the November 14, 2018

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

1. DBS Bank Ltd., DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 30 Apr 2018.

2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA, does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

SINGAPORE

DBS Bank Ltd Contact: Janice Chua 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel. 65-6878 8888 Fax: 65 65353 418 e-mail: equityresearch@dbs.com Company Regn. No. 196800306E

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Nagkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269 e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F JI. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel. 62 21 3003 4900 Fax: 62 21 3003 4943 e-mail: research@id.dbsvickers.com

Bur low

John Perinchery, CMA., CA john.perinchery@emkayglobal.com +91-022-66121374